Analytical Data
-
Gene name
GDN
- Application
-
Alternative Names
SERPINE2; PI7; PN1; PNI; Protease Nexin I; Serpin Peptidase Inhibitor Clade E Member 2; Peptidase inhibitor 7; Protease nexin I
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P07093
-
Expression Region
Ser20~Pro398
-
Molecular Weight
44kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GDN (Glial cell-derived neurotrophic factor) is a crucial protein that plays a significant role in the survival, development, and maintenance of neurons. It is part of the GDNF family of neurotrophic factors, which are essential for the health of dopaminergic neurons and have been implicated in various neurological disorders. Research on GDN has garnered substantial interest due to its potential therapeutic applications, particularly in diseases such as Parkinson's disease, where dopaminergic neuron degeneration leads to severe motor dysfunction. Studies have shown that GDN promotes neuron survival and differentiation, suggesting its use in regenerative medicine and neuroprotection strategies. Additionally, GDN interacts with specific receptors, sparking further exploration into its signaling pathways and mechanisms of action. As a result, the recombinant form of GDN has been developed for research and clinical purposes, aiming to uncover its full potential as a neuroprotective agent and its role in neurodegenerative disease treatments. Understanding the molecular basis of GDN's actions could pave the way for innovative therapeutic interventions, providing hope for improved outcomes in patients affected by neurodegenerative conditions. The ongoing research into GDN and its recombinant forms underscores the urgency and importance of elucidating its properties and enhancing its applications in neuroscience and medicine.
